Prof. Dr. Do-Youn Oh

**Prof. Do-Youn Oh** is a medical oncologist at Seoul National University Hospital's Medical Oncology Center in Seoul, South Korea, specializing in the treatment of gastric, pancreatic, biliary tract and neuroendocrine cancers. He is internationally known as one of the key investigators of practice-changing global clinical trials in gastrointestinal oncology. --- ### Professional Background - __Experience/Years of Work:__ 1997 – Present - __Based In:__ Seoul, South Korea --- ### Innovations & Contributions Prof. Oh is recognized for spearheading the first phase 3 trial that paved the way for immunotherapy as standard of care in advanced biliary tract cancer. - __TOPAZ-1 Principal Investigator:__ Presented data from the global phase 3 TOPAZ-1 trial (NCT03875235) showing that durvalumab in combination with gemcitabine–cisplatin was found to significantly improve overall survival in patients with advanced biliary tract cancer, the first advance in first-line treatment in this disease in more than 10 years. - __Research Output:__ He has published more than 550 peer-reviewed articles and has received more than 18,000 citations, focusing his research on cholangiocarcinoma, pancreatic and gastric cancer therapeutics. - __Drug Development Focus:__ Affiliated with the Cancer Research Institute of Seoul National University College of Medicine, specializes in early-phase clinical trials and drug development in gastrointestinal malignancies. - __Society Memberships:__ ASCO, ESMO, AACR (International); KSMO, KCA, KCSG (Domestic).